<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03332485</url>
  </required_header>
  <id_info>
    <org_study_id>SEB-ECP-202</org_study_id>
    <nct_id>NCT03332485</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of an Edible Colonoscopy Preparation</brief_title>
  <official_title>A Randomized, Investigator- and Colonoscopist-blinded, Phase 2 Study of the Efficacy and Safety of ECP (Polyethylene Glycol 3350 [PEG 3350]) Colon Prep Kit Compared With MoviPrep® Split-dose for Colonoscopy Preparation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sebela Pharmaceuticals Development LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sebela Pharmaceuticals Development LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of ECP (PEG 3350) Colon Prep
      Kit compared with MoviPrep split-dose as a colon-cleansing preparation for colonoscopy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 20, 2017</start_date>
  <completion_date type="Actual">March 14, 2018</completion_date>
  <primary_completion_date type="Actual">March 14, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects with successful bowel cleansing defined as centrally read 4 point modified Aronchick Scale (1=Inadequate, 2=Fair, 3=Good, 4=Excellent) score of either good or excellent.</measure>
    <time_frame>24-hour period, beginning the day prior to the procedure and through the morning of the colonoscopy procedure.</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Colon Prep for Colonoscopy</condition>
  <arm_group>
    <arm_group_label>ECP Colon Prep Kit</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MoviPrep®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ECP Colon Prep Kit</intervention_name>
    <description>ECP Colon Prep Kit</description>
    <arm_group_label>ECP Colon Prep Kit</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MoviPrep®</intervention_name>
    <description>MoviPrep®</description>
    <arm_group_label>MoviPrep®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Scheduled to undergo a medically indicated colonoscopy for colorectal cancer screening
             or surveillance for colorectal cancer

          -  Females must be non-lactating and have a negative pregnancy test if of child bearing
             potential

          -  Ability and willingness of subject to participate fully in all aspects of this
             clinical trial

          -  Written informed consent

        Exclusion Criteria:

          -  Known or suspected clinically significant intestinal stricture of any etiology

          -  History of diabetes mellitus, controlled with insulin

          -  Taking insulin by injection

          -  Pregnant or lactating

          -  Renal insufficiency, hypokalemia, hyperkalemia, chronic liver disease or arrhythmic
             disorder

          -  Chronic heart failure or recent (within 90 days of screening) acute heart failure

          -  Receiving warfarin, heparin, clopidogrel, Pradaxa®, Xarelto®, Effient® or other blood
             thinning agents

          -  Short bowel syndrome

          -  Known diagnosis of Crohn's disease or ulcerative colitis, exclusionary only if subject
             has a history of any bowel resection, has suspected active inflammation, has symptoms
             suggestive of obstruction or a known bowel stricture

          -  Severe psychological disease causing functional impairment limiting capacity to
             complete the preparation

          -  Impaired consciousness increasing the risk of aspiration

          -  Used narcotics/opiates within the 14 days prior to the colonoscopy

          -  Used an anti-diarrheal within the 14 days prior to the colonoscopy procedure

          -  Uses drugs of abuse including abused prescription medication

          -  Used iron supplements within 14 days of the colonoscopy procedure

          -  History of gastrointestinal surgery other than appendectomy or cholecystectomy

          -  Diagnosis of gastroparesis or ileus

          -  Symptoms of chronic constipation defined as fewer than 3 bowel movements per week on
             average over the previous 3 months

          -  History of a failed bowel preparation, defined as either requiring an enema the day of
             the colonoscopy or needing to have the colonoscopy repeated

          -  CTCAE grade 1 sodium, potassium or magnesium at screening

          -  Clinically significant abnormalities (ketones, protein, glucose) at screening
             urinalysis, in the opinion of the investigator

          -  Any known allergies to any of the ingredients or ECP Colon Prep Kit (including
             coconut) or the active comparator

          -  Unable or unwilling to consume all components of the study drug including aversions to
             or adverse events from flavoring

          -  Received any investigational therapy within 30 days of initiation of study drug

          -  Serious underlying disease that, in the opinion of the investigator, may interfere
             with the subject's ability to participate fully in the study

          -  Requirement to use chromoendoscopy during the procedure for the purpose of
             surveillance for colorectal dysplasia or cancer in subjects with inflammatory bowel
             disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sue Hall</last_name>
    <role>Study Director</role>
    <affiliation>Sebela Pharmaceuticals Development LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sebela Site 007</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sebela Site 006</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sebela Site 002</name>
      <address>
        <city>Bastrop</city>
        <state>Louisiana</state>
        <zip>71220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sebela Site 003</name>
      <address>
        <city>Annapolis</city>
        <state>Maryland</state>
        <zip>21401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sebela Site 004</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sebela Site 008</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sebela Site 001</name>
      <address>
        <city>Mentor</city>
        <state>Ohio</state>
        <zip>44060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sebela Site 005</name>
      <address>
        <city>Ogden</city>
        <state>Utah</state>
        <zip>84405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 27, 2017</study_first_submitted>
  <study_first_submitted_qc>November 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2017</study_first_posted>
  <last_update_submitted>March 15, 2018</last_update_submitted>
  <last_update_submitted_qc>March 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polyethylene glycol 3350</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

